JP2020518249A5 - - Google Patents

Info

Publication number

JP2020518249A5

JP2020518249A5 JP2019560107A JP2019560107A JP2020518249A5 JP 2020518249 A5 JP2020518249 A5 JP 2020518249A5 JP 2019560107 A JP2019560107 A JP 2019560107A JP 2019560107 A JP2019560107 A JP 2019560107A JP 2020518249 A5 JP2020518249 A5 JP 2020518249A5

Authority

JP

Japan

Prior art keywords

subunit

seq

human interleukin

amino acid

polypeptide

Prior art date

2018-05-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 101001128431 Homo sapiens Myeloid-derived growth factor Proteins 0.000 claims description 70
• 102000056374 human MYDGF Human genes 0.000 claims description 70
• 125000000539 amino acid group Chemical group 0.000 claims description 68
• 229920001184 polypeptide Polymers 0.000 claims description 58
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 58
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 58
• 235000018417 cysteine Nutrition 0.000 claims description 43
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 41
• 102000015696 Interleukins Human genes 0.000 claims description 36
• 108010063738 Interleukins Proteins 0.000 claims description 36
• 102000039446 nucleic acids Human genes 0.000 claims description 34
• 108020004707 nucleic acids Proteins 0.000 claims description 34
• 150000007523 nucleic acids Chemical class 0.000 claims description 34
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 25
• 239000002773 nucleotide Substances 0.000 claims description 24
• 125000003729 nucleotide group Chemical group 0.000 claims description 24
• 238000000034 method Methods 0.000 claims description 20
• 235000001014 amino acid Nutrition 0.000 claims description 16
• 150000001413 amino acids Chemical group 0.000 claims description 16
• 101100018698 Mus musculus Il27 gene Proteins 0.000 claims description 14
• 230000003248 secreting effect Effects 0.000 claims description 14
• 201000010099 disease Diseases 0.000 claims description 9
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
• 229940024606 amino acid Drugs 0.000 claims description 7
• 230000001254 nonsecretory effect Effects 0.000 claims description 7
• 206010040070 Septic Shock Diseases 0.000 claims description 6
• 230000036303 septic shock Effects 0.000 claims description 6
• 102100036678 Interleukin-27 subunit alpha Human genes 0.000 claims description 5
• 101000852964 Homo sapiens Interleukin-27 subunit beta Proteins 0.000 claims description 4
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
• 102100036712 Interleukin-27 subunit beta Human genes 0.000 claims description 4
• 206010028980 Neoplasm Diseases 0.000 claims description 4
• 230000001154 acute effect Effects 0.000 claims description 4
• 208000006673 asthma Diseases 0.000 claims description 4
• 201000011510 cancer Diseases 0.000 claims description 4
• 230000001684 chronic effect Effects 0.000 claims description 4
• 208000037976 chronic inflammation Diseases 0.000 claims description 4
• 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 4
• 206010012601 diabetes mellitus Diseases 0.000 claims description 4
• 239000003814 drug Substances 0.000 claims description 4
• 208000015181 infectious disease Diseases 0.000 claims description 4
• 208000027866 inflammatory disease Diseases 0.000 claims description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
• 208000023275 Autoimmune disease Diseases 0.000 claims description 3
• 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
• ZFOMKMMPBOQKMC-KXUCPTDWSA-N L-pyrrolysine Chemical group C[C@@H]1CC=N[C@H]1C(=O)NCCCC[C@H]([NH3+])C([O-])=O ZFOMKMMPBOQKMC-KXUCPTDWSA-N 0.000 claims description 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
• 239000013592 cell lysate Substances 0.000 claims description 2
• 208000024908 graft versus host disease Diseases 0.000 claims description 2
• 230000002209 hydrophobic effect Effects 0.000 claims description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
• 229960000310 isoleucine Drugs 0.000 claims description 2
• 238000004519 manufacturing process Methods 0.000 claims description 2
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
• 241000124008 Mammalia Species 0.000 description 4
• 239000004475 Arginine Substances 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 235000013922 glutamic acid Nutrition 0.000 description 3
• 239000004220 glutamic acid Substances 0.000 description 3
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108010066979 Interleukin-27 Proteins 0.000 description 1
• 206010040047 Sepsis Diseases 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 150000001945 cysteines Chemical class 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 208000013223 septicemia Diseases 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1